AFT Thoughts (@AFTFuture2099) header
AFT Thoughts (@AFTFuture2099) profile picture

AI + Future + Tech + Thoughts

Joined February 2024
NEW UPDATE FROM JP 🚨 7 Months after #OCU400 his Vision is improving so much ✅ #Ocugen have the best Therapy for #retinitispigmentosa that will be soon be at Clinics 🚀🚀🚀 @MoreFlax @NattaCop @BRexNew youtu.be/IlAu5uC7MRY?is=N9DX…
3
8
4
58
8,709
AFT Thoughts retweeted
Ocugen CEO @drsmusunuri joined @BBC Correspondent @JamesTGallagher at Cell & Gene Leaders Live to discuss our modifier gene therapy platform and its potential to address vision loss across a broader patient population. #GeneTherapy #Biotech $OCGN
18
2
103
3,501
AFT Thoughts retweeted
Our partnership with Celairis Therapeutics marks our third strategic regional agreement for OCU400 and another important step in advancing our global access strategy. We remain focused on bringing our potential one-time gene therapy closer to patients around the world.
Ocugen is expanding the potential reach of #OCU400 for #retinitispigmentosa through an exclusive licensing agreement with Celairis Therapeutics for #commercialization across Australia, New Zealand, and ASEAN markets with an estimated 725M+ people, following potential U.S. approval. $OCGN 🔗bit.ly/3Vk1ue6
30
3
113
2,069
AFT Thoughts retweeted
Ocugen is expanding the potential reach of #OCU400 for #retinitispigmentosa through an exclusive licensing agreement with Celairis Therapeutics for #commercialization across Australia, New Zealand, and ASEAN markets with an estimated 725M+ people, following potential U.S. approval. $OCGN 🔗bit.ly/3Vk1ue6
31
5
127
7,574
$OCGN #OCUGEN 👇 👇 👇
New Research Report: Ocugen (OCGN) – 3Q26 Reported With Expected Progress In All Three Trials $OCGN #Ocugen #Investing #EquityResearch channelchek.com/news-channel…
12
43
2,275
New Research Report: Ocugen (OCGN) – 3Q26 Reported With Expected Progress In All Three Trials $OCGN #Ocugen #Investing #EquityResearch channelchek.com/news-channel…
15
1
46
2,919
AFT Thoughts retweeted
A milestone-driven third quarter for Ocugen as we continue advancing our pipeline, expanding our global reach, and preparing for potential commercialization. Proud of our team's continued progress and execution.
Today, CEO @drsmusunuri highlighted 3Q 2026 milestones: • #OCU400: Provisional Approval and Priority Designation in the Bahamas and a licensing agreement in MENA + topline results from Phase 3 anticipated in 1Q 2027 • #OCU410: Phase 3 dosing initiated • $84.6M in cash and cash equivalents; runway into 2028 Read: bit.ly/4iW3gLo #QuarterlyUpdate $OCGN
21
4
101
2,851
AFT Thoughts retweeted
Today, CEO @drsmusunuri highlighted 3Q 2026 milestones: • #OCU400: Provisional Approval and Priority Designation in the Bahamas and a licensing agreement in MENA + topline results from Phase 3 anticipated in 1Q 2027 • #OCU410: Phase 3 dosing initiated • $84.6M in cash and cash equivalents; runway into 2028 Read: bit.ly/4iW3gLo #QuarterlyUpdate $OCGN
19
4
92
6,956
$OCGN Roughly 110,000 people live with RP in the US alone. Because OCU400 is gene-agnostic, it can theoretically treat 98% of RP patients who are genetically ineligible for currently approved therapies. A one-time subretinal modifier gene therapy targeting Retinitis Pigmentosa
1
23
702
👇👇👇👇👇
🧬 Received OCU400 for RP? Join our X group and share your experience to help those still waiting for treatment. Your story could give someone hope! ❤️ 👇 Join us! teapaw.org/i/chat/group_join/g211… #OCUGEN #OCU400 #RetinitisPigmentosa #Treatment
46
AFT Thoughts retweeted
$OCGN We’re talking about a pre Rev biotech that’s just months away from pivotal results. If you bought this stock but didn’t buy it for the catalyst, then what exactly were you buying it for, and why have you held this whole time? Over the past year, the stock has ranged from $0.70-$2.50. If SP was your whole reason for buying, could’ve sold at $2.50. But if you actually bet on the products, then buck up buttercup. The current price range is about to be completely irrelevant. Examples of pre rev biotechs heading into pivotal Phase 3 results: 1. ABVX (2025) Bled 72% before Phase 3 results. Then went from $4.77 to $148.83. 2. CPXX (2016) Bled 64% before Phase 3 results. Then went from $1.12 to $30.36. 3. CELC (2025) Bled 66% before Phase 3 results. Then went from $7.58 to $120.32. If this platform validates itself the way the evidence increasingly suggests it will, we’re talking about a market opportunity that makes all those examples look insignificant. 🍻
🤖 Made with AI
3
11
71
2,588
AFT Thoughts retweeted
🧬 Received OCU400 for RP? Join our X group and share your experience to help those still waiting for treatment. Your story could give someone hope! ❤️ 👇 Join us! teapaw.org/i/chat/group_join/g211… #OCUGEN #OCU400 #RetinitisPigmentosa #Treatment
2
1
3
555
🧬 Received OCU400 for RP? Join our X group and share your experience to help those still waiting for treatment. Your story could give someone hope! ❤️ 👇 Join us! teapaw.org/i/chat/group_join/g211… #OCUGEN #OCU400 #RetinitisPigmentosa #Treatment
2
1
3
555
AFT Thoughts retweeted
🚨 OCU400: More than just hope? One patient claims EVERY OCU400 recipient he has spoken to experienced vision improvements. Could this be a turning point for RP patients? 👀 #OCU400 #Ocugen #RetinitisPigmentosa @MoreFlax @NattaCop
1
2
1
17
1,738
Replying to @Ocugen
🚨 OCU400: More than just hope? One patient claims EVERY OCU400 recipient he has spoken to experienced vision improvements. Could this be a turning point for RP patients? 👀 #OCU400 #Ocugen #RetinitisPigmentosa @MoreFlax @NattaCop
1
18
819
🚨 OCU400: More than just hope? One patient claims EVERY OCU400 recipient he has spoken to experienced vision improvements. Could this be a turning point for RP patients? 👀 #OCU400 #Ocugen #RetinitisPigmentosa @MoreFlax @NattaCop
1
2
1
17
1,738
$OCGN #OCUGEN @Ocugen @drsmusunuri .... love seeing patient after patien seeing the improvements. Thank you @Ocugen team!!!
$OCGN The drugs are everything, and nearly every single piece of evidence we see suggests the trials are going damn well. Hearing patient after patient describe their improvements, and now over a year after treatment hearing them say they’re still seeing improvements, is exactly what an investor wants to see with phase 3 results just months away. If this is the norm for people in the trial/EAP, the results will be beyond stellar and well beyond what’s needed to meet the primary endpoint. We’re going from having money riding on a speculative biotech to owning a piece of the next big pharma. 🍻
1
6
38
1,708
AFT Thoughts retweeted
$OCGN The drugs are everything, and nearly every single piece of evidence we see suggests the trials are going damn well. Hearing patient after patient describe their improvements, and now over a year after treatment hearing them say they’re still seeing improvements, is exactly what an investor wants to see with phase 3 results just months away. If this is the norm for people in the trial/EAP, the results will be beyond stellar and well beyond what’s needed to meet the primary endpoint. We’re going from having money riding on a speculative biotech to owning a piece of the next big pharma. 🍻
4
8
1
41
3,917